Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Cardiogenics Holdings,
Inc.
(OTC:CGNH)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
Digital
Angel Corporation
(AMEX:DOC)
Dynavax Technologies
Corporation
(NASDAQ:DVAX)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware Information Systems, Inc. (NASDAQ: MEDW)
Redpoint Bio Corporation
(OTC:RPBC)
| Lpath, Inc., headquartered in San Diego, California, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP(TM) is an antibody against S1P that is presently in Phase 1 clinical trials for the treatment of cancer and also holds promise against multiple sclerosis and various other disorders. A second product candidate, iSONEP(TM) (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical AMD and retinopathy models and has received FDA authorization to begin Phase 1 clinical trials. Lpath's third product candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target (fibrosis, cancer, neuropathic pain). The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company is leveraging to add to its pipeline. |